Share on StockTwits
 

Investment analysts at Canaccord Genuity lifted their price objective on shares of Synageva BioPharma Corp. (NASDAQ:GEVA) from $105.00 to $125.00 in a note issued to investors on Friday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 26.03% from the company’s current price.

Synageva BioPharma Corp. (NASDAQ:GEVA) traded up 1.75% on Friday, hitting $100.92. 37,027 shares of the company’s stock traded hands. Synageva BioPharma Corp. has a 1-year low of $38.58 and a 1-year high of $101.03. The stock’s 50-day moving average is $83.50 and its 200-day moving average is $62.13. The company’s market cap is $3.102 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. upgraded shares of Synageva BioPharma Corp. from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $110.00 price target on the stock, up previously from $60.00. Separately, analysts at Goldman Sachs reiterated a “buy” rating on shares of Synageva BioPharma Corp. in a research note on Tuesday, January 28th. Finally, analysts at Nomura initiated coverage on shares of Synageva BioPharma Corp. in a research note on Wednesday, January 8th. They set a “buy” rating and a $85.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $84.14.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.